DARE - Dare Bioscience Inc Stock Price, Fair Value and News

0.49USD+0.01 (+2.08%)Delayed as of 16 Apr 2024, 02:00 pm ET

Market Summary

USD0.49+0.01

Delayedas of 16 Apr 2024, 02:00 pm

2.08%

DARE Stock Price

View Fullscreen

DARE RSI Chart

DARE Valuation

Market Cap

48.3M

Price/Earnings (Trailing)

-1.6

Price/Sales (Trailing)

17.19

Price/Free Cashflow

-1.22

DARE Price/Sales (Trailing)

DARE Profitability

Return on Equity

598.3%

Return on Assets

-141.9%

Free Cashflow Yield

-81.79%

DARE Fundamentals

DARE Revenue

Revenue (TTM)

2.8M

Rev. Growth (Qtr)

80.79%

DARE Earnings

Earnings (TTM)

-30.2M

Earnings Growth (Yr)

68.04%

Earnings Growth (Qtr)

38.59%

Breaking Down DARE Revenue

52 Week Range

0.451.10

(Low)(High)

Last 7 days

-4%

Last 30 days

2.1%

Last 90 days

50%

Trailing 12 Months

-52.5%

How does DARE drawdown profile look like?

DARE Financial Health

Current Ratio

0.86

DARE Investor Care

Shares Dilution (1Y)

16.71%

Diluted EPS (TTM)

-0.35

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	11.0M	2.8M
2022	4.1M	6.0M	8.0M	10.0M
2021	95.8K	100.0K	100.0K	2.1M
2020	420.8K	308.3K	195.8K	83.3K
2019	637.5K	550.0K	683.3K	533.3K
2018	3.0M	2.5M	992.0K	625.0K
2017	2.5M	2.9M	0	0
2016	0	283.0K	250.0K	1.0M
2014	407.0K	298.0K	189.0K	80.0K
2013	0	0	0	516.0K
2012	0	0	0	625.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Dare Bioscience Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 11, 2019	hawley roger	bought	500,000	1.1	454,545	-

Which funds bought or sold DARE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 11, 2024	First Affirmative Financial Network	added	10.04	2,557	5,986	-%
Apr 04, 2024	IFS Advisors, LLC	unchanged	-	2,066	5,588	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	unchanged	-	-673	1,360	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.11	-525,129	1,065,620	-%
Feb 26, 2024	Virtu Financial LLC	new	-	4,000	4,000	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	unchanged	-	-20,000	39,000	-%
Feb 15, 2024	JANE STREET GROUP, LLC	sold off	-100	-11,549	-	-%
Feb 14, 2024	Zuckerman Investment Group, LLC	unchanged	-	-3,523	7,126	-%
Feb 14, 2024	CITADEL ADVISORS LLC	sold off	-100	-61,136	-	-%
Feb 14, 2024	Royal Bank of Canada	new	-	-	-	-%

Are Funds Buying or Selling DARE?

Are funds buying DARE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DARE

No. of Funds

Unveiling Dare Bioscience Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2022	vanguard index funds	3.99%	3,056,053	SC 13G/A
Feb 09, 2022	vanguard group inc	3.99%	3,056,053	SC 13G/A
Feb 12, 2021	polaris venture partners iii lp	2.4%	1,142,961	SC 13G/A
Feb 10, 2021	vanguard group inc	7.88%	2,993,275	SC 13G
Feb 09, 2021	hudson bay capital management lp	0.92%	382,500	SC 13G/A
Feb 08, 2021	vanguard index funds	7.11%	2,700,357	SC 13G
Apr 01, 2020	hawley roger	4.4%	1,095,105	SC 13D/A
Feb 21, 2020	dare bioscience, inc.	4.5%	1,094,937	SC 13D/A
Feb 12, 2020	polaris venture partners iii lp	4.7%	1,142,961	SC 13G
Dec 09, 2019	dare bioscience, inc.	5.5%	1,084,956	SC 13D/A

Recent SEC filings of Dare Bioscience Inc

View All Filings

Date Filed	Form Type	Document
Mar 29, 2024	S-3	S-3
Mar 29, 2024	S-3	S-3
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	424B5	Prospectus Filed
Mar 28, 2024	10-K	Annual Report
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Jan 29, 2024	3	Insider Trading
Jan 26, 2024	8-K	Current Report

Peers (Alternatives to Dare Bioscience Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	0.01%	-33.89%	-8.42	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.06%	-27.57%	-42.25	10.17	76.23%	61.08%
BMRN	17.3B	2.4B	9.12%	-7.56%	103	7.14	15.42%	18.43%
INCY	12.0B	3.7B	-8.48%	-28.30%	20.07	3.25	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-9.27%	-36.41%	-11.74	15.65	425.83%	18.94%
BBIO	4.5B	-	-6.46%	74.90%	-6.94	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-9.62%	-0.34%	-13.52	11.95	440.80%	-27.84%
ARWR	3.0B	240.7M	-15.06%	-21.14%	-10.03	12.36	-1.03%	-92.09%
ACAD	2.8B	726.4M	-8.60%	-6.11%	-45.41	3.83	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.17%	-12.95%	25.42	4.56	85.90%	-14.05%
NVAX	576.6M	983.7M	-22.12%	-55.02%	-1.06	0.59	-50.36%	17.16%
CRBP	448.6M	881.7K	-2.13%	345.78%	-10.06	466.16	-77.61%	-5.33%
INO	256.8M	4.9M	2.33%	7.75%	-1.9	52.78	-54.97%	51.72%
IBIO	6.7M	2.1M	82.86%	81.13%	-0.25	2.14	-13.45%	66.37%

Dare Bioscience Inc News

Latest updates

Dare Bioscience Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	80.8%	1,807,885	1,000,000	-	-	10,000,000	6,675,000	3,350,000	25,000	25,000	25,000	25,000	25,000	20,833	72,917	125,001	133,333	162,500	112,500	275,000	-	250,000
Operating Expenses	-25.7%	6,979,345	9,396,415	16,230,568	7,138,793	9,615,678	8,400,449	9,543,115	12,668,937	9,162,926	7,693,534	8,440,535	7,581,822	7,125,831	4,254,069	3,860,810	3,418,549	3,982,451	3,083,071	2,958,558	2,621,597	3,624,796
S&GA Expenses	17.0%	3,154,814	2,696,779	3,228,847	2,651,543	2,792,894	2,569,987	2,401,646	2,211,334	1,797,637	1,940,328	1,777,126	1,353,069	1,557,548	1,861,765	1,361,893	1,318,986	1,307,379	1,277,180	1,020,425	1,175,049	1,157,174
R&D Expenses	-43.1%	3,799,531	6,674,636	12,976,721	4,462,250	6,797,784	5,805,462	7,116,469	10,432,603	7,340,289	5,728,206	6,638,409	6,203,753	5,547,450	2,379,804	2,373,916	1,966,230	2,512,572	1,693,391	1,663,133	1,446,548	2,217,622
EBITDA Margin	-	-	-	-	-	-386	-386	-386	-	-	-280	-322	-70.10	-44.52	-32.62	-25.74	-23.82	-29.60	-25.53	-26.04	-23.54	-
EBT Margin	-	-	-	-	-	-386	-386	-386	-	-	-285	-328	-72.84	-46.26	-33.89	-26.74	-24.61	-30.57	-26.37	-26.90	-24.69	-
Net Income	38.6%	-5,096,171	-8,299,096	-15,943,223	-7,019,843	413,998	-8,398,670	-9,542,281	-12,667,429	-9,162,751	-7,323,644	-8,441,474	-7,582,808	-7,124,213	-4,252,248	-3,866,462	-3,393,078	-3,952,450	-3,051,840	-2,916,552	-2,574,475	-3,582,170
Net Income Margin	-188.2%	-10.76	-3.73	-3.09	-3.06	-5.00	-9.80	-18.60	-375	-325	-317	-328	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-9.9%	-8,786,236	-7,995,930	-5,899,369	8,545,226	-8,449,329	-12,348,026	-9,915,899	1,305,807	-11,791,454	-8,377,015	-9,196,127	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-15.1%	21,282	25,054	23,210	30,367	43,826	50,376	51,394	49,187	55,807	48,811	14,822	10,518	7,551	7,662	8,570	10,214	7,443	3,882	7,261	5,020	7,827
Current Assets	-21.8%	17,544	22,435	22,243	29,512	43,039	49,567	50,113	47,817	55,296	48,243	14,059	9,599	6,984	6,984	7,777	9,322	6,444	3,243	6,562	4,260	7,240
Cash Equivalents	-22.2%	10,811	13,894	13,329	19,829	34,670	40,390	32,071	39,317	51,674	45,571	9,112	7,660	4,669	5,389	5,347	5,047	4,780	2,435	5,631	3,505	6,806
Net PPE	1019.0%	656	59.00	46.00	55.00	65.00	73.00	21.00	25.00	26.00	33.00	25.00	32.00	38.00	42.00	55.00	52.00	64.00	6.00	7.00	8.00	9.00
Goodwill	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	-3.7%	26,330	27,343	25,929	25,395	32,714	24,033	18,361	18,308	17,053	16,923	7,078	7,260	8,702	9,048	8,259	7,000	7,002	2,072	2,178	1,239	1,101
Current Liabilities	-22.3%	20,480	26,343	24,701	24,338	31,624	22,838	16,537	16,395	16,053	15,907	6,005	6,108	7,661	7,965	6,084	4,716	5,612	1,889	1,974	1,016	1,091
Shareholder's Equity	-Infinity%	-5,047	-	-	4,972	11,112	26,344	33,033	30,879	38,754	31,889	7,744	3,258	-	-	311	3,214	441	1,810	5,083	3,780	6,727
Retained Earnings	-3.0%	-171,236	-166,178	-157,900	-149,100	-141,074	-125,131	-118,100	-118,500	-110,126	-100,584	-87,917	-78,800	-71,430	-62,989	-55,399	-48,300	-44,023	-40,156	-36,800	-32,021	-28,969
Additional Paid-In Capital	1.4%	166,539	164,299	155,556	154,453	152,530	151,997	151,437	149,560	149,028	132,636	95,763	82,106	70,366	61,713	55,822	51,613	44,565	42,077	41,942	35,890	35,792
Shares Outstanding	1.7%	99,974	98,292	86,634	86,179	84,825	85,553	84,683	83,944	83,944	70,776	47,486	44,503	41,596	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	102,284	-	-	-	85,850	-	-	-	22,800	-	-	-	12,232	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-2.6%	-8,178	-7,973	-6,586	-16,117	-5,896	8,600	-8,448	-12,343	-9,915	1,320	-11,791	-8,377	-9,193	-5,356	-4,086	-6,597	-3,808	-3,180	-3,018	-3,308	-2,710
Share Based Compensation	-2.6%	620	636	650	625	532	556	538	532	389	439	405	366	199	195	187	161	118	135	111	98.00	81.00
Cashflow From Investing	-2648.2%	-607	-22.10	-	-	-2.70	-55.00	-816*	-4.55	-	-14.52	-	-	-2.38	-	-	-	6,144	-	-	-	-
Cashflow From Financing	-38.1%	5,309	8,576	452	1,299	-1*	4.00	1,339	-	16,004	35,217	13,252	11,375	8,455	5,399	4,390	6,888	-	-	5,152	-	-2.50

DARE Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue
Total revenue	$ 2,807,885	$ 10,000,000
Operating expenses
General and administrative	12,109,691	11,243,271
Research and development	21,538,074	30,042,217
License fee expense	100,000	100,000
Total operating expenses	33,747,765	41,385,488
Loss from operations	(30,939,880)	(31,385,488)
Other income	778,489	437,750
Net loss	(30,161,391)	(30,947,738)
Net loss to common stockholders	(30,161,391)	(30,947,738)
Foreign currency translation adjustments	(9,585)	(196,338)
Comprehensive loss	$ (30,170,976)	$ (31,144,076)
Loss per common share - basic (in usd per share)	$ (0.35)	$ (0.37)
Loss per common share - diluted (in usd per share)	$ (0.35)	$ (0.37)
Weighted average number of common shares outstanding:
Basic (in shares)	87,303,701	84,571,805
Diluted (in shares)	87,303,701	84,571,805
License fee revenue
Revenue
Total revenue	$ 1,000,000	$ 10,000,000
Milestone revenue
Revenue
Total revenue	1,800,000	0
Royalty revenue
Revenue
Total revenue	$ 7,885	$ 0

DARE Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 10,476,056	$ 34,669,605
Other receivables	949,211	1,703,160
Prepaid expenses	6,118,272	6,665,988
Total current assets	17,543,539	43,038,753
Property and equipment, net	655,975	64,908
Deposits	1,163,477	10,502
Operating lease right-of-use assets	1,319,630	457,925
Other non-current assets	599,594	254,295
Total assets	21,282,215	43,826,383
Current Liabilities
Accounts payable	3,385,551	2,027,953
Accrued expenses	2,889,005	10,894,016
Deferred grant funding	13,737,154	18,303,567
Current portion of lease liabilities	468,726	398,391
Total current liabilities	20,480,436	31,623,927
Deferred revenue, non-current	1,000,000	1,000,000
Liability related to the sale of future royalties, net	3,913,676	0
Lease liabilities long-term	935,743	90,346
Total liabilities	26,329,855	32,714,273
Commitments and contingencies (Note 12)
Stockholders' equity (deficit)
Preferred stock issued	0	0
Common stock, $0.0001 par value, 240,000,000 shares authorized, 99,973,932 and 84,825,481 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	9,997	8,482
Additional paid-in capital	166,539,290	152,529,579
Accumulated other comprehensive loss	(360,896)	(351,311)
Accumulated deficit	(171,236,031)	(141,074,640)
Total stockholders' equity (deficit)	(5,047,640)	11,112,110
Total liabilities and stockholders' equity (deficit)	$ 21,282,215	$ 43,826,383
Common stock, shares authorized (in shares)	240,000,000	240,000,000

About Dare Bioscience Inc

DarÃƒÂ© Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder; and DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy. The company's Phase I-ready products are DARE-VVA1, a proprietary formulation of tamoxifen for intravaginal to treat vulvar vaginal atrophy in women with hormone-receptor positive breast cancer; DARE-PDM1, a proprietary hydrogel formulation of diclofenac, a nonsteroidal anti-inflammatory drug, for vaginal administration as a treatment for dysmenorrhea; DARE-204 and DARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-GML, an intravaginally-delivered potential multi-target antimicrobial agent formulated with glycerol monolaurate; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. DarÃƒÂ© Bioscience, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

CEO	Ms. Sabrina Martucci Johnson
WEBSITE	darebioscience.com
INDUSTRY	Biotechnology
EMPLOYEES	25

Dare Bioscience Inc Frequently Asked Questions

What is the ticker symbol for Dare Bioscience Inc? What does DARE stand for in stocks?

DARE is the stock ticker symbol of Dare Bioscience Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Dare Bioscience Inc (DARE)?

As of Mon Apr 15 2024, market cap of Dare Bioscience Inc is 48.28 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DARE stock?

You can check DARE's fair value in chart for subscribers.

What is the fair value of DARE stock?

You can check DARE's fair value in chart for subscribers. The fair value of Dare Bioscience Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Dare Bioscience Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DARE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Dare Bioscience Inc a good stock to buy?

The fair value guage provides a quick view whether DARE is over valued or under valued. Whether Dare Bioscience Inc is cheap or expensive depends on the assumptions which impact Dare Bioscience Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DARE.

What is Dare Bioscience Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, DARE's PE ratio (Price to Earnings) is -1.6 and Price to Sales (PS) ratio is 17.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DARE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Dare Bioscience Inc's stock?

In the past 10 years, Dare Bioscience Inc has provided -0.388 (multiply by 100 for percentage) rate of return.